<DOC>
	<DOCNO>NCT01667471</DOCNO>
	<brief_summary>This long-term , open-label extension study evaluate safety RoActemra/Actemra ( tocilizumab ) patient polyarticular-course juvenile idiopathic arthritis complete WA19977 core study . Patients age 9-18 year least JIA ACR30 clinical response RoActemra/Actemra core study eligible receive RoActemra/Actemra 8 mg/kg intravenously every 4 week . Anticipated time study treatment 104 week .</brief_summary>
	<brief_title>A Long-Term Extension Study RoActemra/Actemra ( Tocilizumab ) Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Patients 9 18 year age complete visit 33 ( week 104 ) WA19977 study least JIA ACR30 clinical response RoActemra/Actemra relative baseline WA19977 , AEs , SAEs condition lead unacceptable risk continue treatment Scheduled receive first RoActemra/Actemra infusion study 4 6 week last IV infusion core study Females childbearing potential male female partner childbearing potential must agree use effective contraception define protocol Patients , accord investigator judgment , satisfactory benefit RoActemra/Actemra therapy within WA19977 Treatment investigational agent since last administration study drug core study WA19977 current participation another clinical trial except WA19977 Patient develop autoimmune rheumatic disease overlap syndrome permitted polyarticularcourse JIA subset : rheumatoid factor positive negative JIA extend oligoarticular JIA Patient pregnant , lactating , intend become pregnant study 12 week last administration study drug Any significant concomitant disease medical surgical condition History significant allergic infusion reaction prior biologic therapy Known current active acute , subacute , chronic history recurrent infection ; patient suffer ongoing active infection Epstein Barr virus , herpes zoster recurrent history urinary tract infection include ( acute ) infection exclude subsided Positive latent tuberculosis ( TB ) Currently active asthma patient require use oral parenteral corticosteroid &gt; /= 2 week within 6 month prior enter study Inadequate hepatic , renal bone marrow function</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>